All-trans retinoic acid and rapamycin normalize Hutchinson Gilford progeria fibroblast phenotype

Oncotarget

Volumn 6, Issue 30, 2015, Pages 29914-29928

  Pellegrini, Camilla ^a,b   Columbaro, Marta ^b   Capanni, Cristina ^a,b   D'Apice, Maria Rosaria ^c   Cavallo, Carola ^b   Murdocca, Michela ^d   Lattanzi, Giovanna ^a,b   Squarzoni, Stefano ^a,b  

^a CNR   (Italy)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

All trans retinoic acid; DNA damage and repair; Hutchinson gilford progeria syndrome; Premature aging; Rapamycin

Indexed keywords

BARRIER TO AUTOINTEGRATION FACTOR; CELL PROTEIN; LAMIN A; LAMIN C; LAP2ALPHA PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PRELAMIN A PROTEIN; PROGERIN PROTEIN; RAPAMYCIN; RETINOIC ACID; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BANF1 PROTEIN, HUMAN; DNA BINDING PROTEIN; HISTONE; LAMINA-ASSOCIATED POLYPEPTIDE 2; LYSINE; MEMBRANE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUCLEAR PROTEIN; PARP1 PROTEIN, HUMAN; PRELAMIN A;

ARTICLE; CASE REPORT; CELL CYCLE G2 PHASE; CELL POPULATION; CELL PROLIFERATION; CHILD; CHROMATIN STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FIBROBLAST; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LMNA GENE; NUCLEAR SHAPE; PHENOTYPE; PROGERIA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SCHOOL CHILD; WILD TYPE; CELL CULTURE; CELL CYCLE; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENETICS; METABOLISM; METHYLATION; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CELLS, CULTURED; DNA-BINDING PROTEINS; DRUG SYNERGISM; FIBROBLASTS; GENE EXPRESSION; HISTONES; HUMANS; LAMIN TYPE A; LYSINE; MEMBRANE PROTEINS; METHYLATION; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, FLUORESCENCE; NUCLEAR PROTEINS; PHENOTYPE; POLY (ADP-RIBOSE) POLYMERASE-1; POLY(ADP-RIBOSE) POLYMERASES; PROGERIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIROLIMUS; TRETINOIN;

EID: 84945143871     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4939     Document Type: Article

References (53)

1. Moir RD, Spann TP. The structure and function of nuclear lamins: implications for disease. Cell Mol Life Sci. 2001; 58:1748-1757.
2. Prokocimer M, Barkan R, Gruenbaum Y. HutchinsonGilford progeria syndrome through the lens of transcription. Aging Cell. 2013; 12:533-543.
3. Lopez-Soler RI, Moir RD, Spann TP, Stick R, Goldman RD. A role for nuclear lamins in nuclear envelope assembly. J Cell Biol. 2001; 154:61-70.
4. Meta M, Yang S, Bergo M, Fong L, Young S. Protein farnesyltransferase inhibitors and progeria. Trends Mol Med. 2006; 12:480-487.
5. Columbaro M, Capanni C, Mattioli E, Novelli G, Parnaik V, Squarzoni S, Maraldi N, Lattanzi G. Rescue of heterochromatin organization in Hutchinson-Gilford progeria by drug treatment. Cell Mol Life Sci. 2005; 62:2669-2678.
6. Corrigan DP, Kuszczak D, Rusinol AE, Thewke DP, Hrycyna CA, Michaelis S, Sinensky MS. Prelamin A endoproteolytic processing in vitro by recombinant Zmpste24. Biochem J. 2005; 387:129-138.
7. Young S, Fong L, Michaelis S. Prelamin, A, Zmpste24, misshapen cell nuclei, and progeria-new evidence suggesting that protein farnesylation could be important for disease pathogenesis. J Lipid Res. 2005; 46:2531-2558.
8. Lattanzi G. Prelamin A-mediated nuclear envelope dynamics in normal and laminopathic cells. Biochem Soc Trans. England. 2011; 1698-1704.
9. Mounkes LC, Stewart CL. Aging and nuclear organization: lamins and progeria. Curr Opin Cell Biol. 2004; 16:322-327.
10. González JM, Andrés V. Synthesis, transport and incorporation into the nuclear envelope of A-type lamins and inner nuclear membrane proteins. Biochem Soc Trans. 2011; 39:1758-1763.
11. Merideth M, Gordon L, Clauss S, Sachdev V, Smith A, Perry M, Brewer C, Zalewski C, Kim H, Solomon B, Brooks B, Gerber L, Turner M, Domingo D, Hart T, Graf J, et al. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med. 2008; 358:592-604.
12. Pollex RL, Hegele RA. Hutchinson-Gilford progeria syndrome. Clin Genet. 2004; 66:375-381.
13. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, Durkin S, Csoka AB, Boehnke M, Glover TW, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 2003; 423:293-298.
14. Capell BC, Collins FS. Human laminopathies: nuclei gone genetically awry. Nat Rev Genet. 2006; 7:940-952.
15. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, Lyonnet S, Stewart CL, Munnich A, Le Merrer M, Lévy N. Lamin a truncation in HutchinsonGilford progeria. Science. 2003; 300:2055.
16. Panigrahi RG, Panigrahi A, Vijayakumar P, Choudhury P, Bhuyan SK, Bhuyan R, Maragathavalli G, Pati AR. Hutchinson-gilford progeria syndrome: a rare genetic disorder. Case Rep Dent. 2013; 2013:631378.
17. Mehta IS, Eskiw CH, Arican HD, Kill IR, Bridger JM. Farnesyltransferase inhibitor treatment restores chromosome territory positions and active chromosome dynamics in Hutchinson-Gilford progeria syndrome cells. Genome Biol. 2011; 12:R74.
18. Zhavoronkov A, Smit-McBride Z, Guinan KJ, Litovchenko M, Moskalev A. Potential therapeutic approaches for modulating expression and accumulation of defective lamin A in laminopathies and age-related diseases. J Mol Med (Berl). 2012; 90:1361-1389.
19. Cau P, Navarro C, Harhouri K, Roll P, Sigaudy S, Kaspi E, Perrin S, De Sandre-Giovannoli A, Lévy N. Nuclear matrix, nuclear envelope and premature aging syndromes in a translational research perspective. Semin Cell Dev Biol. 2014.
20. Osorio FG, Navarro CL, Cadiñanos J, López-Mejía IC, Quirós PM, Bartoli C, Rivera J, Tazi J, Guzmán G, Varela I, Depetris D, de Carlos F, Cobo J, Andrés V, De Sandre-Giovannoli A, Freije JM, et al. Splicing-directed therapy in a new mouse model of human accelerated aging. Sci Transl Med. 2011; 3:106ra107.
21. Gordon LB, Kleinman ME, Miller DT, Neuberg DS, Giobbie-Hurder A, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland R, Snyder BD, Fligor B, Bishop WR, Statkevich P, Regen A, Sonis A, Riley S, et al. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:16666-16671.
22. Varela I, Pereira S, Ugalde AP, Navarro CL, Suárez MF, Cau P, Cadiñanos J, Osorio FG, Foray N, Cobo J, de Carlos F, Lévy N, Freije JM, López-Otín C. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med. 2008; 14:767-772.
23. Cenni V, Capanni C, Columbaro M, Ortolani M, D'Apice MR, Novelli G, Fini M, Marmiroli S, Scarano E, Maraldi NM, Squarzoni S, Prencipe S, Lattanzi G. Autophagic degradation of farnesylated prelamin A as a therapeutic approach to lamin-linked progeria. European journal of histochemistry: EJH. 2011; 55:e36.
24. Mendelsohn AR, Larrick JW. Rapamycin as an antiaging therapeutic?: targeting mammalian target of rapamycin to treat Hutchinson-Gilford progeria and neurodegenerative diseases. Rejuvenation Res. 2011; 14:437-441.
25. Cao K, Graziotto JJ, Blair CD, Mazzulli JR, Erdos MR, Krainc D, Collins FS. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in HutchinsonGilford progeria syndrome cells. Sci Transl Med. 2011; 3:89ra58.
26. Bjedov I, Partridge L. A longer and healthier life with TOR down-regulation: genetics and drugs. Biochem Soc Trans. 2011; 39:460-465.
27. Arancio W. A bioinformatics analysis of Lamin-A regulatory network: a perspective on epigenetic involvement in Hutchinson-Gilford progeria syndrome. Rejuvenation Res. 2012; 15:123-127.
28. Olins AL, Herrmann H, Lichter P, Kratzmeier M, Doenecke D, Olins DE. Nuclear envelope and chromatin compositional differences comparing undifferentiated and retinoic acid-and phorbol ester-treated HL-60 cells. Exp Cell Res. 2001; 268:115-127.
29. Saito A, Sugawara A, Uruno A, Kudo M, Kagechika H, Sato Y, Owada Y, Kondo H, Sato M, Kurabayashi M, Imaizumi M, Tsuchiya S, Ito S. All-trans retinoic acid induces in vitro angiogenesis via retinoic acid receptor: possible involvement of paracrine effects of endogenous vascular endothelial growth factor signaling. Endocrinology. 2007; 148:1412-1423.
30. Swift J, Ivanovska IL, Buxboim A, Harada T, Dingal PC, Pinter J, Pajerowski JD, Spinler KR, Shin JW, Tewari M, Rehfeldt F, Speicher DW, Discher DE. Nuclear lamin-A scales with tissue stiffness and enhances matrix-directed differentiation. Science. 2013; 341:1240104.
31. Tee MK, Vigne JL, Taylor RN. All-trans retinoic acid inhibits vascular endothelial growth factor expression in a cell model of neutrophil activation. Endocrinology. 2006; 147:1264-1270.
32. Okumura K, Nakamachi K, Hosoe Y, Nakajima N. Identification of a novel retinoic acid-responsive element within the lamin A/C promoter. Biochem Biophys Res Commun. 2000; 269:197-202.
33. Okumura K, Hosoe Y, Nakajima N. c-Jun and Sp1 family are critical for retinoic acid induction of the lamin A/C retinoic acid-responsive element. Biochem Biophys Res Commun. 2004; 320:487-492.
34. Rajawat Y, Hilioti Z, Bossis I. Autophagy: a target for retinoic acids. Autophagy. 2010; 6:1224-1226.
35. Rajawat Y, Hilioti Z, Bossis I. Retinoic acid induces autophagosome maturation through redistribution of the cation-independent mannose-6-phosphate receptor. Antioxid Redox Signal. 2011; 14:2165-2177.
36. Cenni V, Capanni C, Columbaro M, Ortolani M, D'Apice MR, Novelli G, Fini M, Marmiroli S, Scarano E, Maraldi NM, Squarzoni S, Prencipe S, Lattanzi G. Autophagic degradation of farnesylated prelamin A as a therapeutic approach to lamin-linked progeria. Eur J Histochem. Italy. 2011; e36.
37. Camozzi D, Capanni C, Cenni V, Mattioli E, Columbaro M, Squarzoni S, Lattanzi G. Diverse lamin-dependent mechanisms interact to control chromatin dynamics: Focus on laminopathies. Nucleus. 2014; 5.
38. Shumaker D, Dechat T, Kohlmaier A, Adam S, Bozovsky M, Erdos M, Eriksson M, Goldman A, Khuon S, Collins F, Jenuwein T, Goldman R. Mutant nuclear lamin A leads to progressive alterations of epigenetic control in premature aging. Proc Natl Acad Sci U S A. 2006; 103:8703-8708.
39. Capanni C, Cenni V, Haraguchi T, Squarzoni S, Schuchner S, Ogris E, Novelli G, Maraldi N, Lattanzi G. Lamin A precursor induces barrier-to-autointegration factor nuclear localization. Cell Cycle. United States: 2010 Landes Bioscience2010; 2600-2610.
40. Lattanzi G, Columbaro M, Mattioli E, Cenni V, Camozzi D, Wehnert M, Santi S, Riccio M, Del Coco R, Maraldi N, Squarzoni S, Foisner R, Capanni C. Pre-Lamin A processing is linked to heterochromatin organization. J Cell Biochem. 2007; 102:1149-1159.
41. Zhang H, Xiong ZM, Cao K. Mechanisms controlling the smooth muscle cell death in progeria via down-regulation of poly(ADP-ribose) polymerase1. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111:E2261-2270.
42. Korolchuk VI, Menzies FM, Rubinsztein DC. Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett. (Netherlands: 2009 Federation of European Biochemical Societies. Published by Elsevier B.V). 2010; 1393-1398.
43. Liu Y, Wang Y, Rusinol A, Sinensky M, Liu J, Shell S, Zou Y. Involvement of xeroderma pigmentosum group A (XPA) in progeria arising from defective maturation of prelamin A. FASEB J. 2008; 22:603-611.
44. Liu B, Wang Z, Zhang L, Ghosh S, Zheng H, Zhou Z. Depleting the methyltransferase Suv39 h1 improves DNA repair and extends lifespan in a progeria mouse model. Nat Commun. 2013; 4:1868.
45. Scaffidi P, Misteli T. Lamin A-dependent nuclear defects in human aging. Science. 2006; 312:1059-1063.
46. Rahim R, Strobl JS. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Anticancer Drugs. 2009; 20:736-745.
47. Zhang H, Xiong ZM, Cao K. Mechanisms controlling the smooth muscle cell death in progeria via down-regulation of poly(ADP-ribose) polymerase1. Proc Natl Acad Sci U S A. 2014.
48. Montes de Oca R, Shoemaker CJ, Gucek M, Cole RN, Wilson KL. Barrier-to-autointegration factor proteome reveals chromatin-regulatory partners. PloS one. 2009; 4:e7050.
49. Capanni C, Squarzoni S, Cenni V, D'Apice MR, Gambineri A, Novelli G, Wehnert M, Pasquali R, Maraldi NM, Lattanzi G. Familial partial lipodystrophy, mandibuloacral dysplasia and restrictive dermopathy feature barrier-to-autointegration factor (BAF) nuclear redistribution. Cell Cycle. 2012.
50. Richards SA, Muter J, Ritchie P, Lattanzi G, Hutchison CJ. The accumulation of un-repairable DNA damage in laminopathy progeria fibroblasts is caused by ROS generation and is prevented by treatment with N-acetyl cysteine. Human molecular genetics. 2011; 20:3997-4004.
51. Zuchegna C, Aceto F, Bertoni A, Romano A, Perillo B, Laccetti P, Gottesman ME, Avvedimento EV, Porcellini A. Mechanism of retinoic acid-induced transcription: histone code, DNA oxidation and formation of chromatin loops. Nucleic acids research. 2014; 42:11040-11055.
52. Verstraeten VL, Peckham LA, Olive M, Capell BC, Collins FS, Nabel EG, Young SG, Fong LG, Lammerding J. Protein farnesylation inhibitors cause donut-shaped cell nuclei attributable to a centrosome separation defect. Proc Natl Acad Sci U S A. 2011; 108:4997-5002.
53. Cenni V, Capanni C, Mattioli E, Columbaro M, Wehnert M, Ortolani M, Fini M, Novelli G, Bertacchini J, Maraldi NM, Marmiroli S, D'Apice MR, Prencipe S, Squarzoni S, Lattanzi G. Rapamycin treatment of Mandibuloacral Dysplasia cells rescues localization of chromatin-associated proteins and cell cycle dynamics. Aging. 2014; 6:755-770.